Modifications of the previously described LHRH antagonists, [Ac‐d‐Nal(2)1, d‐Phe(4Cl)2, d‐Trp3, d‐Cit6, d‐Ala10]LHRH and the corresponding d‐Hci6 analogue, have been made to alter the hydrophobicity of the N‐terminal acetyl‐tripeptide portion. Substitution of d‐Trp3 with the less hydrophobic d‐Pal(3) had only marginal effects on the antagonistic activities and receptor binding potencies of the d‐Cit/d‐Hci6 analogues, but it appeared to further improve the toxicity lowering effect of d‐Cit/d‐Hci6 substitution. Antagonists containing d‐Pal(3)3 and d‐Cit/d‐Hci6 residues, i.e. [Ac‐d‐Nal(2)1, d‐Phe(4Cl)2, d‐Pal(3)3d‐Cit6, d‐Ala10]LHRH (SB‐75) and [Ac‐d‐Nal(2)1, d‐Phe(4Cl)2, d‐Pal(3)3, d‐Hci6, d‐Ala10]LHRH (SB‐88), were completely free of the toxic effects, such as cyanosis and respiratory depression leading to death, which have been observed in rats with the d‐Trp3, d‐Arg6 antagonist and related antagonists. Replacement of the N‐acetyl group with the hydrophilic carbamoyl group caused a slight decrease in antagonistic activities, particularly in vitro. Introduction of urethane type acyl group such as methoxycarbonyl (Moc) or t‐butoxycarbonyl (Boc) led to analogues that showed LHRH‐potentiating effect. The increase in potency induced by these analogues, e.g. [Moc‐d‐Nal(2)1, d‐Phe(4Cl)2, d‐Trp3, d‐Cit6, d‐Ala10]LHRH and [Boc‐d‐Phe1, d‐Phe(4Cl)2, d‐Pal(3)3, d‐Cit6, d‐Ala10]LHRH, was 170‐260% and persisted for more than 2 h when studied in a superfused rat pituitary system.